About petvivo holdings inc - PETV
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. Its lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.
PETV At a Glance
PetVivo Holdings, Inc.
5151 Edina Industrial Boulevard
Edina, Minnesota 55439
| Phone | 1-952-405-6216 | Revenue | 1.14M | |
| Industry | Medical Specialties | Net Income | -10,473,672.00 | |
| Sector | Health Technology | 2026 Sales Growth | 0.801% | |
| Fiscal Year-end | 03 / 2027 | Employees | 22 | |
| View SEC Filings |
PETV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 18.49 |
| Price to Book Ratio | 11.436 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.811 |
| Enterprise Value to Sales | 18.517 |
| Total Debt to Enterprise Value | 0.018 |
PETV Efficiency
| Revenue/Employee | 51,891.227 |
| Income Per Employee | -476,076.00 |
| Receivables Turnover | 1.629 |
| Total Asset Turnover | 0.177 |
PETV Liquidity
| Current Ratio | 1.35 |
| Quick Ratio | 0.96 |
| Cash Ratio | 0.255 |
PETV Profitability
| Gross Margin | 18.558 |
| Operating Margin | -706.282 |
| Pretax Margin | -917.45 |
| Net Margin | -917.45 |
| Return on Assets | -162.182 |
| Return on Equity | -326.349 |
| Return on Total Capital | -406.649 |
| Return on Invested Capital | -290.055 |
PETV Capital Structure
| Total Debt to Total Equity | 17.102 |
| Total Debt to Total Capital | 14.605 |
| Total Debt to Total Assets | 10.517 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |